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1. Introduction 
Endometrial cancer is the second most common cancer of the female reproductive organs 
after cervical cancer in China. The depth of myometrial invasion is the most important factor 
for treatment selection and prognosis predictionȜ1ȝ. Magnetic resonance imaging (MRI) 
provides high spatial resolution and excellent soft tissue contrast. The contrast of tumors to 
uterine cavity and myometrium can be further improved with the use of contrast agents and 
the enhancement features of tumors at different stages can be analyzed quantitatively and 
dynamicallyȜ5ȝ. However, the relationship between the clinical stages and differentiation 
degrees of endometrial cancer and the time-intensity curve (TIC) types or the enhancement 
rates is still not clear on the dynamic contrast-enhanced MRI (DCE-MRI). This study aimed 
to explore the relationship between the quantitative data of DCE-MRI and the staging of 
endometrial cancer by investigating the DCE-MRI characteristics of endometrial cancer at 
different stages, and thus to evaluate the usefulness of the quantitative data and the TIC 
types of MRI in the diagnosis of endometrial cancer and identification of their degrees of 
differentiation.  
2. Methods 
2.1 Cases 
A retrospective analysis of 24 patients with endometrial cancer from April 2007 to July 
2009 was performed. The diagnosis was confirmed with diagnostic curettage in all 
patients. The 24 patients received MRI examination in our hospital and of them, 15 
patients underwent MRI within 1 week after surgery. The mean age of the patients was 
55.8 years, ranging from 28 to 77. Eight patients were pre-menopausal and 16 were post-
menopausal. The clinical symptoms included postmenopausal vaginal bleeding in 19 
cases, increased vaginal discharge in 2 cases, increased menstrual flow and extended 
menstrual period in 1 case, and contact bleeding in 2 cases. Informed written consent was 
obtained from all patients. 
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2.2 MRI techniques 
MRI was performed using GE 1.5T Signa HD Echospeed Superconducting Scanner with 
body phased-array. Intrauterine device was removed from each patient who had it and all 
patients were asked to drink about 500 ml water to make the bladder moderate full 1 h 
before the scanning. Conventional MRI was first performed with the sequences of SE T1-
weighted imaging (T1WI) and fat-suppressed FSE T2-weighted imaging (T2WI). DCE-MRI 
was then performed in 9 patients with horizontal surface fast spoiled gradient echo (FSPGR) 
sequence and in 15 patients with sagittal liver volume T1-weighted ultra-fast three-
dimensional imaging (liver acquisition with volume acceleration, LAVA). MR scanning 
ranged from the upper edge of the iliac wing to the level of bilateral femoral neck with 
patients in the supine position. For DCE-MRI, Gd-DTPA contrast agent (0.1 mmol/kg) was 
given to each patient through antecubital vein using a high-pressure syringe with a flow 
rate of 2.5 ml/s. Scanning was taken at 16, 32, 48, 64, and 300 seconds (s), respectively, after 
injection. The scanning parameters were summarized in Table 1. 
2.3 Image analysis 
2.3.1 Analysis of the tumor characteristics 
2.3.1.1 General types 
Two types were classified: diffuse type and focal type. Diffuse type was defined as extensive 
thickening of the uterine endometrium (>3 mm for menopause and >10 mm for pre-
menopausal patients). The focal type was defined as the formation of soft-tissue mass. 
2.3.1.2 Invasion depth 
Two groups were divided. One group referred to the tumors with no myometrial invasion 
(intact junctional zone and homogeneous low signal on T2WI) or with superficial 
myometrial invasion (depth of the myometrial invasion, ≤1/2). Another group referred to 
the tumors with deep myometrial invasion (myometrial invasion, >1/2). 
 
 
 
 
 
 
Note: FSPGR: fast spoiled gradient echo sequence; LAVA: liver volume three-dimensional ultra-fast 
T1WI sequence. 
 
Table 1. The sequence parameters of MRI. 
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2.3.1.3 Cervical invasion 
All tumors were divided into two groups: without cervical invasion and with cervical 
invasion.  
2.3.1.4 Infiltration width 
Tumors were classified into two groups. One group was the lesions limited within the 
uterus, and another group was those with invasion into the parametrium or adjacent organs, 
or with metastasis. 
2.3.2 Region Of Interest (ROI) 
The ROI of the tumors or ROI1 was selected from the scanning section with the maximum 
tumor diameter and the contrast-enhanced area of the solid part (> 0.1 cm2). The control 
or ROI2 was selected from the adjacent unaffected myometrial tissue, and its size and 
shape were kept same to those of ROI1. Necrosis, hemorrhage, and other areas with 
heterogeneous signal were avoided on the basis of the characteristics of conventional 
MRI.  
2.3.3 Quantitative measurements 
The DCE TIC was obtained directly from the GE functool 4.3 workstation. The signal 
intensity in the different DCE phases was measured in the ROI1 and ROI2, respectively. The 
enhanced rate in each phase was calculated as enhanced rate = (SIpost-SIpre)/SIpre×100%. 
SIpost was the enhanced signal intensity in the ROI and SIpre was the corresponding signal 
intensity before the enhancement. The enhanced rate at 16 s was recorded as the arterial 
phase relative signal increase (ARSI%) and the enhanced rate at the curve peak was 
recorded as the maximal relative signal increase (MRSI%). The signal enhancement ratio 
(SER%) was calculated as SER% = (SImax-SIprior)/(SIe-SIprior) × 100%. SImax was the 
maximum signal intensity from the DCE TIC, and SIe was the signal intensity during the 
delayed period. 
2.3.4 TIC types 
The time period of enhancement to 32 s after injection of contrast agent was set to the early 
phase; the time period from 32 s to 64 s was set to the middle phase; the time period from 64 
s was set to the late phase; and the time period from 300 s was set to the delayed phase. 
Thus the TIC of endometrial cancer could be divided into four typesȜ6ȝ: type I: early and 
rapid enhancement to the peak in the early phase with the ARSI% ≥ 60%; type II: similar 
enhancement pattern in the early phase to type I, but with the ARSI% <60%; type III: 
significant enhancement in the early phase with the ARSI% ≥ 60%, but showing continued 
enhancement in the middle and late phases; and type IV: lack of rapid enhancement in the 
early phase with ARSI% < 60%, but showing continued enhancement. 
2.3.5 Endometrial cancer staging based on pathology 
The pathological information of 15 postoperative cases was collected by two physicians. The 
general type, differentiation degree, and invasion depth on MRI were compared with the 
corresponding findings in pathology which was used as the gold standard. The other 9 cases 
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without operative treatment were staged comprehensively based on the clinical information, 
mainly the gynecological specialized examination, B-mode ultrasound, cystoscopy, and 
colonoscopyȜ7ȝ. 
2.4 Statistical analysis 
Statistical analysis was performed with the SPSS 11.5 statistical software package. Paired t-
test was used to compare the signal intensity in different DCE phases between cancer 
lesions and adjacent myometrial tissues. Two independent samples t-test was used to 
compare the differences of ARSI%, MRSI%, and SER% among groups. P < 0.05 was 
considered to be significant. 
3. Results 
3.1 Pathological findings and MRI features 
3.1.1 Pathological findings 
Pathologically, 16 tumors were adenocarcinoma, 5 were adenosquamous cell carcinoma, 1 
was serous adenocarcinoma, 1 was papillary adenocarcinoma, and 1 was clear cell 
carcinoma. In addition, 12 of the 24 tumors were well differentiated and the other 12 were 
poorly differentiated. 
3.1.2 Features of MRI 
3.1.2.1 General types 
Nineteen tumors exhibited diffuse type with the endometrial thickness of 1.12 ~ 10.35 cm 
(4.68 ± 0.33 cm in average). Five tumors exhibited focal type with the maximum diameter of 
0.94 ~ 6.17 cm (3.27 ± 0.42 cm in average). 
3.1.2.2 Depth of invasion 
Fifteen tumors showed no invasion or superficial myometrial invasion, and the other 9 
tumors showed deep myometrial invasion. 
3.1.2.3 Cervical involvement 
Nine tumors had no involvement of the cervix and 15 tumors invaded the cervix. 
3.1.2.4 Infiltration width 
There were 20 tumors without peripheral invasion, 1 tumor with parametrial invasion, 1 
tumor with right sacral metastasis, and 2 tumors with lymph node metastasis. 
3.2 DCE TIC types 
All 24 tumors were enhanced at 16 s after contrast agent injection. Of them, 17 tumors 
showed lower or similar enhancement and the other 7 tumors showed significantly higher 
enhancement compared with the adjacent normal myometrium tissues. On TIC, 23 tumors 
exhibited continued enhancement in the late phase, and only 1 tumor exhibited decreased 
enhancement (Figures 1-4). Based on the TIC types, we found type I in 12 tumors (12/24), 
type II in 6 tumors (6 / 24), type III in 3 tumors (3 / 24), and type IV in 3 tumors (3 / 24). 
Types I and II curves with an early peak were observed in 18 tumors (18/24). ARSI% ≥ 60% 
in types I and III curves was observed in 15 tumors (15/24) (Figures 5-8). 
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Fig. 1 to 4 female, 61 years old, endometrial adenocarcinoma. Figure 1 showed 0 s after the 
contrast agent injection, endometrial cancer lesions showed slightly lower signal, such as 
uterine tissue showed equal signal; Figure 2-4 16 s, 32 s and 64 s after the contrast agent 
injection, endometrial cancer lesions showed moderate enhancement, and normal uterine 
tissue was significantly enhanced, contrast between them was clear. Figure 5-12 Dynamic 
enhancement curves (TIC) type. Figure 5 endometrial cancer lesions (curve 1)was type I, 
ARSI% ≥ 60%, reached peak in early dynamic contrast-enhanced; normal tissue (curve 2) 
showed type III, ARSI% ≥ 60%, continuing to strengthen and enhance level higher than 
lesion; Figure 6 endometrial cancer lesions (curve 1) showed type II, ARSI% <60%, also 
reached its peak in the early dynamics; normal tissue (curve 2) showed type I, strengthening 
was higher than the lesion; Figure 7 endometrial cancer lesions (curve 1) showed type II 
curve, normal tissue (curve 2) showed type IV, ARSI% <60%, degree of enhancement was 
similar with lesions; Figure 8 endometrial cancer lesions (curve 1) showed type III, normal 
tissue (curve 2) showed type IV, the degree of enhancement below the lesion. 
www.intechopen.com
 
Diagnostic Value of Dynamic Contrast-Enhanced MRI in Endometrial Cancer 
 
73 
The signal intensities of the tumors in the early phase (16 s), delayed phase (300 s), or the 
curve peak were significantly lower than those of the adjacent normal tissue. The signal 
intensity in tumors was significantly higher in the delayed phase than in the early phase 
(Table 2). Also, the mean values were all significantly higher for SER% in the menopausal 
group than in the non-menopausal group, for ARSI% in the poorly differentiated group than 
in well differentiated group, and for ARSI% in the deep myometrial invasion group than in 
the superficial or no myometrial invasion group (all P < 0.05 ) (Table 3). 
 
tissue 16 s 300 s peak 
endometrial 
carcinoma 
716.48±215.10 802.71±289.34 879.33±280.96 
normal 893.94±354.52 1110.83±288.83 1183.18±318.13 
t -2.911 -4.926 -4.7 
P P＜0.01 P＜0.01 P＜0.01 
Table 2. Comparison of the signal intensity in the early and delayed phases between normal 
tissues and endometrial carcinoma (%,±s). 
 
enhanced 
rate 
menopause 
t P 
general types 
t P 
yes no diffuse localized 
ARSI% 1.06±0.50 1.03±0.48 0.132 0.896 1.07±0.45 0.95±0.61 0.492 0.628 
MRSI% 1.56±0.75 1.92±0.72 -1.139 0.267 1.69±0.78 1.68±0.67 0.016 0.988 
SER% 1.27±0.23 1.07±0.19 2.095 0.048 1.22±0.24 1.12±0.22 0.87 0.394 
enhanced 
rate 
differentiation 
degree 
t P 
infiltration depth 
t P 
  well poorly 
no / 
superficial 
deep 
ARSI% 0.80±0.38 1.20±0.48 2.142 0.044 0.86±0.34 1.37±0.52 2.917 0.008 
MRSI% 1.86±0.88 1.58±0.67 -0.862 0.398 1.66±0.75 1.73±0.78 0.231 0.819 
SER% 1.13±0.22 1.25±0.24 1.17 0.254 1.17±0.23 1.25±0.24 0.762 0.454 
enhanced 
rate 
cervical involvement 
t P 
Infiltration breadth 
t P 
  yes no yes no 
ARSI% 1.19±0.53 0.82±0.28 1.955 0.063 1.34±0.70 0.99±0.42 1.364 0.186 
MRSI% 1.73±0.81 1.61±0.66 0.388 0.702 1.90±0.80 1.64±0.75 0.63 0.535 
SER% 1.17±0.23 1.26±0.24 -0.848 0.406 1.27±0.31 1.19±0.22 0.643 0.527 
Note: ARSI%: arterial phase relative signal increase; MRSI%: maximal relative signal increase; SER%: 
signal enhancement ratio. 
Table 3. Comparison of the ARSI%, MRSI%, and SER% between designated groups (%,). 
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4. Discussion 
4.1 Endometrial cancer characteristics of DCE-MRI 
Currently, staging of uterine lesions is often determined based on the findings of multi-
phase enhanced MRI in clinic, however, the selection of the enhanced phases is 
controversialȜ8ȝ. DCE-MRI is a dynamic MR technology, focusing on the enhancement 
behaviors at different time points and reflecting the characteristics of tumor blood 
supplyȜ9ȝ. Therefore, the tumor blood vessels can be quantified to a certain extent, which 
makes it possible to study the microvascular characteristics non-invasively. 
It has been reportedȜ5ȝthat a mild thin-like enhancement can be observed in the thin layer of 
tissue between endometrium and myometrium in the early phase of DCE-MRI, which is 
called subendometrial enhancement (SEE). Similarly, because of the difference in blood 
supply between tumor and myometrial tissue, the signal enhancement in tumors is 
significantly lower than that in normal tissue, which leads to increased contrast between 
tumor and myometrium. Until to the delayed phase, the tumor enhancement is increasing, 
but the intensity in tumor is still lower than that in myometrium. The maximum signal 
difference between tumor and myometrium can be observed at certain time, at which the 
tumor size and margin can be seen clearly and accurate estimation of the invasion depth to 
myometrium can be made. In the present study, all 24 endometrial tumors were enhanced 
on DCE-MRI. The enhancement degree in 17 tumors was lower than that in the normal 
tissue in the early phase, which was consistent with the literature. The remaining 7 tumors 
showed significantly stronger enhancement than the normal tissues, and of the tumors, 3 
were poorly differentiated adenocarcinoma, 1 was clear cell carcinoma, and 1 was serous 
carcinoma. These results suggest that the enhancement degree may be associated with the 
degree of malignancy as more abundant blood supply in higher malignant tumors. Only 1 
tumor showed decreased contrast enhancement in the delayed phase, which was 
inconsistent with the report in the literature. The maximum signal intensity in the delayed 
phase was lower in the tumors than in the adjacent normal tissue, but the signal intensity 
difference between tumors and normal tissues was higher in the delayed phase than in the 
early phase, consistent with the previous reportsȜ10-11ȝ, indicating that the delayed phase 
(300 s) was more favorable to delineate the lesions on DCE-MRI. 
4.2 Quantitative evaluation of enhancement and TIC curves 
Enhanced patterns of tumors reflect the trend of enhancement, however there is no 
quantitative criterion for the enhancement evaluation. In recent years, many investigators 
measured the degree of the lesion enhancement with ARSI%, MRSI%, SER%, and other 
indicators, in addition to the detection sensitivity, noise, etc. These indicators reflect the 
degree of tumor angiogenesis and the status of blood supply. ARSI% reflects the relative 
degree of enhancement in the early phase, MRSI% reflects the maximum degree of 
enhancement, and SER% reflects the relative degree of enhancement in the delayed phase. 
Our study showed that the mean value of ARSI% was significantly higher in poorly 
differentiated tumors than in well differentiated tumors, which was consistent with the 
findings by Yamashit et al.Ȝ12ȝwho showed that the poorer the tumor differentiation was, 
the richer blood supply in the early phase there was. They also showed that ARSI% could be 
used to evaluate the prognosis to a certain extent. Bronow et al. foundȜ1ȝ that the metastasis 
probabilities in the pelvic and para-aortic lymph nodes were 2.5% and 1.2%, respectively, if 
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the tumor limited in the endometrium, while those probabilities were 46.4% and 28.5%, 
respectively, if tumors had deep myometrial invasion. Therefore, precise evaluation of the 
depth of myometrial invasion is critical for the clinical treatment selection and prognosis 
prediction. In our study, the ARSI% in deep myometrial invasion group was higher than in 
the no/superficial myometrial invasion group. The mean value of SER% in post-
menopausal group was higher than in non-menopausal group, which may be due to the 
reasons of uterine atrophy, increased fiber content, and a larger extracellular space in post-
menopausal women. Patients diagnosed with cervical involvement should expand the scope 
of operation, or take surgery after the radiotherapy. Seki et al.Ȝ5ȝ used DCE sequences in the 
detection of cervical involvement and they showed diagnostic accuracy of 95%, higher than 
85% obtained on T2WI. Our study showed that the mean value of ARSI% in cervical 
involvement group was higher than in the unaffected group, but the difference was not 
significant. Further study is necessary in a large sample of tumors. 
Regarding the TIC curves of the 24 endometrial cancers, 18 (18/24) were types I and II with 
an early peak and16 (16/24) were types I and III with ARSI% ≥ 60% and an early 
enhancement. All these endometrial cancers were those with rich blood supply. 
In short, the signal enhancement of endometrial cancers in different phases of DCE-MRI can 
be quantitatively measured, which reflects the status of the tumor's blood supply, and 
indirectly provides information on their biology. The data in the early and delayed phases of 
DCE-MRI could provide more relevant information for prognosis prediction and tumor 
stage determination. 
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